Incidence and survival of pediatric and adult hepatocellular carcinoma, United States, 2001-2020

Co-Authors Azlann Arnett[a,e] David A. Siegel[b], Shifan Dai[c], Trevor D. Thompson[b], Jennifer Foster[a,e], Erika di Pierro[a,e], Behnoosh Momin[b], Philip J. Lupo[a,d,e], Andras Heczey[a,e]

Affiliations:

[a]Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas

[b]Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

[c]Cyberdata Technologies, Inc., Herndon, Virginia

[d]Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

[e]Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

Corresponding Author: Andras Heczey MD; Address: 1102 Bates Avenue C1760.10, Houston, TX, 77025. Phone: 832-824-4233; E-mail: heczey@bcm.edu

KEY POINTS

Question: How does incidence and survival compare between pediatric and adult hepatocellular carcinoma (HCC)?

Findings: In contrast to adults, pediatric incidence rates of HCC were stable, and no demographic risk factors for incidence were identified. Pediatric HCC survival was higher than adults. Non-Hispanic Black race and ethnicity, small metropolitan county, and non-fibrolamellar histology, were risk factors in both pediatric and adult groups.

Meaning: Non-Hispanic Black patients and those living in smaller metropolitan and non-metropolitan areas irrespective of age might benefit from further research in outcome disparities, provider education, and prospective studies to maximize outcomes through effective risk-adapted management strategies.

ABSTRACT

Importance Hepatocellular carcinoma (HCC) accounts for approximately 80% of liver neoplasms. Globally, HCC ranks as the third most lethal cancer, with the number of HCC-related deaths expected to further increase by 2040. In adults, disparities in incidence and survival are well described while the epidemiology of pediatric HCC is not well characterized.

Objective To describe incidence and survival for pediatric (ages 0-19 years) HCC cases and compare these measures to adults (ages ≥20 years) diagnosed with HCC. We evaluated demographic factors and clinical characteristics that influence incidence and outcomes.

Design Population-based cohort study

Setting Incidence data from the US Cancer Statistics (USCS) database from 2003 to 2020 and 5-year relative survival from the National Program of Cancer Registries (NPCR) from 2001 to 2019, covering 97% and 83% of the US population, respectively.

Participants 355,349 (USCS) and 257,406 (NPCR) patients were identified using ICD-O-3 C22.0 and 8170-5 codes.

Main Outcomes and Measures Incidence annual percent change (APC) and average APC (AAPC) using joinpoint regression. Five-year relative survival. All-cause survival estimated using multivariate Cox modeling. Corresponding 95% confidence intervals (CI) were calculated.

Results HCC incidence rate per 100,000 persons was 0.056 (95%CI:0.052-0.060) for pediatric cases and 7.793 (7.767-7.819) for adults. Incidence was stable in the pediatric population (0.3 AAPC, -1.1-1.7). In contrast, after periods of increase, incidence declined in adults after 2015 (-1.5 APC). Relative survival increased over time for both pediatric and adult ages and was higher for children and adolescents (46.4%, 95%CI:42.4-50.3) than adults (20.7%, 95%CI:20.5-20.9) overall and when stratified by stage. Regression modeling showed that non-Hispanic Black race and ethnicity was associated with higher risk of death in children and adolescents (1.48, 95%CI:1.07-2.05) and adults (1.11, 95%CI:1.09-1.12) compared to non-Hispanic white race and ethnicity.

Conclusions and Relevance Between 2003 and 2020 in the United States, pediatric HCC incidence was stable while incidence in adults began to decline after 2015. Survival was higher across all stages for children and adolescents compared to adults. Non-Hispanic Black race and ethnicity showed a higher risk of death for both age groups. Further studies could explore the factors that influence these outcome disparities.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. HCC has the sixth highest incidence and ranks third for cancer-related deaths with 1.4 million new cases and 1.3 million deaths per year predicted by 2040[1]. In children, HCC typically occurs in the absence of cirrhosis and is frequently associated with predisposing conditions while in adults, hepatitis C virus (HCV), alcoholic liver disease, and metabolic dysfunction-associated steatosis liver disease (MASLD) drive disease pathogenesis[2–5]. Overall, pediatric and adult HCC have comparable histology and are classified similarly though potential biological differences remain to be fully understood[6,7].

HCC epidemiology has been well characterized in adults but is not well described in children.[ ] Reports from the Surveillance Epidemiology and End Results (SEER) database, which covered <30% of the US population, the incidence of pediatric HCC is 0.5-0.59 per million persons[2–4]. Compared to adult studies, analyses of racial and ethnic disparities in pediatric HCC have reported inconsistent results[2–5,8]. Thus, there is a need for in-depth studies with high population coverage to contextualize results from case series and other small sample studies
.

We analyze pediatric and adult HCC incidence and outcome data sourced from the United States Cancer Statistics (USCS) and National Program Cancer Registries (NPCR) databases, which cover 97% and 83% of the population, respectively. We compare results by age to highlight differences and similarities that may inform patient management, public health planning and practice, and disease prevention efforts for these populations.

METHODS

Incidence data from 2003-2020 were obtained from USCS, which combines data from the NPCR (Centers for Disease Control and Prevention, CDC) and SEER programs. USCS includes all 50 states and the District of Columbia. This analysis covered 97% of the United States population as Nevada and Indiana were excluded due to incomplete data. Five-year survival data were collected from NPCR-funded registries from 2001-2019 and either had active case follow-up or were linked to the CDC's National Death Index. NPCR covered 83% of the US population, excluding data from Connecticut, Hawaii, Iowa, Indiana, Massachusetts, Michigan, New Mexico, Nevada, South Dakota, Virginia, and Washington. Data from Kansas, Minnesota, North Dakota, and

Wisconsin were excluded from the regression and survival curve analysis due to incomplete data. Unknown histological subtype or racial and ethnic group were additionally excluded. Cases were identified using International Classification of Disease for Oncology third edition (ICD-O-3) anatomy code C22.0 and histology codes 8170 (HCC not otherwise specified), 8171 (fibrolamellar), 8172 (scirrhous), 8173 (spindle cell variant), 8174 (clear cell type), and 8175 (pleomorphic type)[9]. Only primary tumors were included, and cases identified by autopsy or death certificate were excluded.

Data was stratified into ages 0-19 years old (pediatric cases: children and adolescents), and 20 years or older (adult cases), 0-14, 15-19, 20-29, 30-39, 40-64, and 65 years and older. Cases were stratified by sex, race and ethnicity, merged summary stage (local, regional, or distant)[10], diagnosis year, metropolitan status by county, county-based economic status,[11] and histology (fibrolamellar [8171] compared to all other HCC subtypes [8170, 8172-5]). Five-year relative survival (RS) was measured from 2001-2007 versus 2008-2019, corresponding to before and after Sorafenib approval for HCC in adults. For all analyses, statistics were not shown if a cell represented <6 cases.

Incidence was measured by counts and rates per 100,000 persons. Rates were age-adjusted using the 2000 United States standard population. Incidence trends were measured in annual percent change (APC) and average APC (AAPC) and calculated using Joinpoint software and defined as significant if different from zero using an alpha of 0.05. Trend analysis did not include the year 2020 due to data changes related to the COVID-19 pandemic[12]. Relative risk of incidence (RR) was estimated using negative binomial regression.

Five-year RS, defined as survival in the absence of death from other causes, was calculated via the complete method using expected life tables in SEER*Stat 8.4.2 (National Cancer Institute). RS results were considered different if 95% confidence intervals (CI) did not overlap. All-cause survival curves, overall and by demographic and clinical variables, were generated using the Kaplan–Meier method. Statistical testing for survival curves was performed using the log-rank test. Multivariable Cox proportional hazards modeling used separate models for pediatric and adult ages. Missing data were imputed (m=10 imputations) using the aregImpute function (Hmisc package in R). All predictor and outcome variables were included in the imputation process. Non-Hispanic American Indian/Alaska Native (NHAIAN) and Asian/Pacific Islander (NHAPI) patients were combined in regression analysis. The linearity assumption for continuous predictors was tested using restricted cubic spline functions. The proportional hazards (PH) assumption was assessed using the Schoenfeld residual

correlation test. Schoenfeld residual plots were used to help determine time intervals within which the PH assumption holds. Histology violated the PH assumption in the model for children and adolescents. Therefore, a histology x time (<1 year vs. >1-5 years) interaction was included in the model to satisfy the PH assumption. Due to the large power to detect non-proportional hazards in the adult population, most variables violated the PH assumption. This violation was ignored so the hazard ratio (HR) presented among adults represent the average effect over five years of follow-up. Analysis was performed using SAS version 9.4 and R version 4.2.1.

RESULTS

Incidence of hepatocellular carcinoma

During 2003-2020, the pediatric incidence rate was 0.056 (95%CI:0.052-0.060; Table 1). In adults, the incidence rate was (7.793, 95%CI:7.767-7.819). Overall incidence was stable in the pediatric population at 0.3 average annual percent change (AAPC, 95%CI:-1.1-1.7) with no joinpoints identified (Fig.1A). In adults, AAPC was 2.9 (95%CI:2.8-3.1) driven by an initial increase from 2003-2009 (APC of 5.8) and 2009-2015 (3.0), and then declined during 2015-2019 (-1.5) (Fig. 1B).

In adults, the incidence of localized (3.707, 95%CI:3.690-3.725) was higher than regional (1.948, 95%CI:1.935-1.961) or distant disease (1.137, 95%CI:1.127-1.147). Among pediatric cases, incidence was similar for localized (0.021, 95%CI:0.018-0.023), regional (0.017, 95%CI:0.015-0.019), and distant disease (0.016, 95%CI:0.014-0.018) (Fig.1E).

There was no overall difference in incidence between pediatric (0.022, 95%CI:0.020-0.024) and adult (0.021, 95%CI:0.020-0.023) fibrolamellar HCC (fHCC) (Table 1). The incidence of fHCC was less than that of other HCC types in all age groups, except for adolescents (15-19 years) who had the highest incidence (0.046, 95%CI:0.059-0.064) (Table S1).

In children and adolescents, HCC incidence was similar between males (0.058, 95%CI:0.053-0.064) and females (0.054, 95%CI:0.048-0.059). In contrast, in adults, males had a higher incidence of HCC (12.891, 95%CI:12.842-12.941) compared to females (3.363, 95%CI:3.339-3.386) (Fig.1D). For pediatric HCC, incidence was similar regardless of race and ethnicity, while it varied in adults (Fig. 1 E).

Relative risk (RR) of developing HCC was analyzed in pediatric and adult populations. Risk increased with age in both pediatric and adult groups. Individuals aged 15-19 years (p<0.001) had higher risk compared to those aged 0-14 years (3.15 95%CI:2.73-3.64), and risk was higher (p<0.001) for all older age groups in adults compared to individuals in the 20–29-year group (Table S2). In adults, racial and ethnic group, socioeconomic status, and metropolitan county size, were risk factors, but were similar for pediatric ages.

Five-year relative survival of patients with hepatocellular carcinoma

Pediatric 5-year RS was 46.4% (95%CI:42.4-50.3) and was 20.7% (95%CI:20.5-20.9; Table 2) in adults. Survival was lower with increasing disease stage for both pediatric and adult populations. Pediatric cases had better outcomes compared to adults for all stages: localized disease (75.1%, 95%CI:68.8-80.4 versus 33.6%, 95%CI:33.3-34.0), regional (44.5%, 95%CI:37.1-51.6 versus 12.0% 11.7-12.2), and distant disease (14.1%, 95%CI:9.5-19.7 versus 3.5%, 95%CI:3.2-3.7), in children versus adults, respectively (Fig.2A).

In adults, 5-year RS for with fHCC (35.3%, 95%CI:31.9-39.8) was better than for those with other HCC subtypes (20.7%, 95%CI:20.5-20.9), but these measures were similar in pediatric cases (49.3%, 95%CI:42.7-55.6 versus 44.8%, 95%CI:39.8-49.7, respectively). Unlike other HCC types, survival reported for fHCC did not improve between 2001 and 2007 versus 2008 and 2019 for either pediatric (47.3%, 95%CI:36.7-57.2 versus 50.7%, 95%CI:42.1-58.6) or adult populations (33.3%, 95%CI:27.3-39.5 versus 37.6%, 95%CI:32.4-42.7).

Over time, in adults, RS increased overall from 16.4% (95%CI:16.1-16.7) between 2001 and 2007 to 22.2% (95%CI:22.0-22.4) between 2008 and 2019. In pediatric ages during the same periods, RS increased from 37.6% (95%CI:31.7-43.5) to 52.3% (95%CI:47.0-57.3).

Pediatric ages had similar RS between males (46.8%, 95%CI:41.4-52.0) and females (46.0%, 95%CI:40.0-51.7). In adults, RS was lower in males (19.9%, 95%CI:19.7-20.1) than females (23.7, 95%CI:23.3-24.1) (Fig.2B). RS was also similar in pediatric ages regardless of race and ethnicity but varied in adults (Fig.2C).

All-cause survival analysis

In children and adolescents, the risk of death within five years was significantly lower for cases diagnosed in 2008 or later compared to those diagnosed from 2001 to 2007 (HR =0.69, 95%CI:0.55-0.86). Compared to local disease, regional (HR=3.10, 95%CI:2.22-4.32), and distant (HR=7.18, 95%CI:5.25-9.82) disease stages

were associated with a higher risk of death. Histology was also a significant predictor of 5-year survival (p<0.0001), although this relationship varied over time. Fibrolamellar HCC was associated with a lower risk of death within the first year of follow-up compared to other HCC histology types (HR=0.38, 95%CI:0.26-0.55) but after one year, the risk of death within five years for fHCC vs other HCC types was similar (HR=1.06, 95%CI:0.77-1.48). Non-Hispanic Black race and ethnicity showed higher risk of death compared to non-Hispanic White race and ethnicity (HR=1.48, 95%CI:1.07-2.05). Children and adolescents diagnosed in counties with a metropolitan population of 250,000–1 million (HR=1.36, 95%CI:1.02-1.82) and non-metropolitan areas (HR=1.45, 95%CI:1.01-2.08) had a higher risk of death compared to those diagnosed in metropolitan counties with a population >1 million. Age, sex, and county economic status were not significant predictors of five-year survival (Fig.3A, Fig.S1, Fig.S2).

In adults, we assessed later diagnosis year per 1-year increase as the data was linear (HR=0.97, 95%CI:0.97-0.97). Compared to adults with local disease, regional (HR-2.07, 95%CI:2.05-2.09) and distant disease (HR=3.79, 95%CI:3.75-3.84) were also associated higher risk of death. Fibrolamellar HCC (HR=0.59, 95%CI:0.54-0.65) was associated with a lower risk of death compared to other histological types of HCC. Male sex (HR=1.10, 95%CI:1.09-1.12), non-Hispanic Black race and ethnicity (HR=1.11, 95%CI:1.09-1.12 compared to non-Hispanic White), bottom 25% (HR=1.15, 95%CI:1.13-1.16 compared to top 25%) and 25%-75% county economic status (HR=1.08, 95%CI:1.07-1.09), and lower county population were all associated with higher risk of death (Fig. 3B, Fig.S1, Fig.S2). Age was associated with higher risk of death although the relationship was non-linear (Fig.3C).

DISCUSSION

Using data from high coverage databases, we described the incidence and survival of children, adolescents, and adults with HCC. We show that the recent decline in HCC incidence described in adults has not occurred in children and adolescents with HCC, extending findings from smaller studies and suggesting that incidence in children has been stable since 1973[2,3,13–17]. It is possible that the etiological shift from HCV- to MASLD -driven disease that has been proposed to explain this trend in adults may not apply to children[13–17]. Pediatric MASLD incidence is increasing in the United States, and it is unclear if the increase in this risk factor would lead to an increase in HCC in children. Our data demonstrates unchanged incidence of HCC despite the increase in pediatric MASLD in the US[13–16,18,19].

We show that among pediatric ages, most are diagnosed with local disease as opposed to regional or distant disease, clarifying conflicting results from prior smaller studies[2–4]. Moreover, consistent with a prior study, we show that children and adolescents are more frequently diagnosed with advanced disease than adults[4]. This finding likely reflects the higher proportion of *de novo* HCC in children, as these cases are diagnosed at more advanced disease stage while adults are surveilled after onset of cirrhosis[20].

Our results confirm the well-established higher incidence of HCC in adult males versus females[2–5,13,14]. In contrast to most studies in the pediatric population, we found no difference in HCC incidence based on sex[2–5]. Recently, it was shown that the male-to-female ratio declined in adults aged <50 years from 2009-2015, with multiple studies showing a faster decline in incidence among males than females in recent years[13–15]. This shift from a predominantly male disease has been linked by age-period-cohort analysis to recent shifts in etiology[13].

We found no increased risk of developing HCC based on demographic factors in children and adolescents. In contrast, in adults there were clear disparities based on race and ethnicity, metropolitan status, and socioeconomic status highlighting the need to incorporate demographic factors in the prevention and treatment of HCC in adults. This difference is likely due to the different etiologies in children versus adults[2,3,5,8,13–17]. Consistent with the adult literature, we show an increase in risk with age, which in children likely reflects the higher incidence of fHCC in adolescents[2–4,13].

Interestingly, risk of death from HCC did not increase linearly with age, instead showing a plateau before a sharp increase in older ages. Although younger adults more frequently present with less favorable tumor characteristics, preserved liver function in younger individuals, more aggressive therapy, and better post-operative recovery may all contribute to this effect[21–23].

Survival was higher in pediatric ages compared to adults regardless of disease stage, however pediatric ages had a higher proportion of advanced disease overall. Surgery remains the cornerstone of treatment for both pediatric and adult HCC[2,4,24]. A higher proportion of pediatric patients undergo surgery than adults, possibly due to the lower prevalence of underlying liver disease; this likely contributes to better survival for pediatric patients[4]. Multivariate analysis showed that survival improved in all groups over time, with risk of death decreasing linearly with later year of diagnosis in adults. Both children and adults had better survival in 2008-

2019 versus 2001-2007. In pediatric cases, survival improved over time in all stages, but confidence intervals overlapped.

Consistent with other reports, we found that adult females with HCC survived longer than males. This is consistent with the idea that sex hormones may play a role in improving the survival of women with HCC[8]. In children, however, we found no difference between the sexes while previous reports present mixed findings[2,3,8,24].

We found a 48% higher risk of death at 5 years for non-Hispanic Black compared to non-Hispanic White children and adolescents and an 11% higher risk for non-Hispanic Black compared to non-Hispanic White adults. This effect was apparent after controlling for socio-economic status and disease stage, which are known to influence racial and ethnic disparities[8,25]. Moreover, we did not find a significant difference in survival among pediatric ages according to socioeconomic status that was described in the adult population. Collectively, this disparity may be mediated by known differences in quality of care, and poor provider-patient interactions including bias or distrust.[8,24,26,27]. Kahla et al. recently published a similar finding in hepatoblastoma[28]. This may point to broader inequity in the treatment of liver disease that may be driven by unequal transplant care, particularly living donor transplant and waitlist mortality that are partially independent of economic status[29,30]. We also found lower survival in smaller metropolitan counties, similar to what has been described for adults with HCC, which may reflect decreased quality of care[31].

Consistent with previous population-based studies, we found that fHCC was associated with better overall survival compared to all other HCC histological types. Prior studies attributed this difference to more aggressive surgical treatment, less frequent underlying liver disease, less aggressive biology, and younger age of patients with fHCC[2-4,32-34]. This finding remains controversial as the International Childhood Liver Tumors Strategy Group (SIOPEL) reported no difference in three-year follow-up between fHCC and HCC but better one-year survival in HCC[35]. Our study reconciles the results from SIOPEL and those of population-based studies. We found lower risk in pediatric ages within one year of follow-up, but no difference with longer follow up times, possibly due to higher complete resection rate or delayed follow-up in fHCC[32-35]. While adults with fHCC had better overall survival than adults with other HCCs, the survival benefit persists beyond one year, possibly due to lower resection rates and higher frequency of underlying liver disease in adults compared to children[32-35]. Importantly, we found that fHCC survival did not improve in the 2008-2019 period compared to

2001-2017 unlike other HCC type survival, suggesting that fHCC-specific treatments may be needed to improve outcomes.

We acknowledge several limitations of our study. First, there were insufficient numbers of NHAIAN or NHAPI cases to consider these groups separately in our survival analyses. We may be underpowered to detect small differences in incidence based on race and ethnicity. Additionally, due to significant heterogeneity and large sample size in the adult population, we were unable to satisfy the proportional hazards assumption for the multivariate survival analysis. We acknowledge that county-wide measures of socioeconomic status and population may not capture significant heterogeneity within each county. Our study is limited to the information contained in the USCS and NPCR databases and provides no validated information relating to etiology, tumor characteristics beyond stage, or treatment such as surgery.

In summary, the incidence of pediatric HCC remained stable between 2003-2019, unlike the adult population that experienced a recent decrease. We show that several of the demographic disparities found in adults do not extend to children and adolescents, including the higher incidence in males and in racial and ethnic groups other than non-Hispanic White, as well as better survival in females. We describe several novel differences in outcomes including a higher risk of death for non-Hispanic Black children, adolescents, and adults; additional research and potential interventions may improve outcomes in this population[36]. We are also the first to report on metropolitan and area-level socioeconomic status in pediatric HCC, showing a similar higher in risk of death for both pediatric and adult ages associated with decreasing county size; future research may be helpful to better understand this pattern for pediatric ages. Lastly, this is the first population-based study to confirm that compared to other HCC types, the previously described survival benefit in children with fHCC is limited to short-term follow up and does not translate to long term survival. While there are similarities between pediatric and adult HCC, there are several important differences that highlight the need for age-specific (pediatric vs adult) research and risk-adapted management strategies that incorporate the demographic vulnerabilities defined here for patients with HCC.

References

1. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. *J Hepatol*. 2022;77(6):1598-1606. doi:10.1016/j.jhep.2022.08.021

2. McAteer JP, Goldin AB, Healey PJ, Gow KW. Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes. *J Pediatr Surg*. 2013;48(11):2194-2201. doi:10.1016/j.jpedsurg.2013.05.007

3. Allan BJ, Wang B, Davis JS, et al. A review of 218 pediatric cases of hepatocellular carcinoma. *J Pediatr Surg*. 2014;49(1):166-171; discussion 171. doi:10.1016/j.jpedsurg.2013.09.050

4. Lau CSM, Mahendraraj K, Chamberlain RS. Hepatocellular Carcinoma in the Pediatric Population: A Population Based Clinical Outcomes Study Involving 257 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2011). *HPB Surg*. 2015;2015:670728. doi:10.1155/2015/670728

5. Khanna R, Verma SK. Pediatric hepatocellular carcinoma. *World J Gastroenterol*. 2018;24(35):3980-3999. doi:10.3748/wjg.v24.i35.3980

6. Czauderna P. Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment. *Med Pediatr Oncol*. 2002;39(5):519-523. doi:10.1002/mpo.10178

7. Weeda VB, Aronson DC, Verheij J, Lamers WH. Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. *Pediatric Blood & Cancer*. 2019;66(2):e27475. doi:10.1002/pbc.27475

8. Guo A, Pomenti S, Wattacheril J. Health Disparities in Screening, Diagnosis, and Treatment of Hepatocellular Carcinoma. *Clin Liver Dis (Hoboken)*. 2021;17(5):353-358. doi:10.1002/cld.1057

9. World Health Organization. *International Classification of Diseases for Oncology (ICD-O)*. 3rd ed., 1st revision. World Health Organization; 2013. Accessed March 15, 2024. https://iris.who.int/handle/10665/96612

10. Review of Staging Systems | SEER Training. Accessed March 15, 2024. https://training.seer.cancer.gov/collaborative/intro/systems_review.html

11. Distressed Designation and County Economic Status Classification System. Appalachian Regional Commission. Accessed December 1, 2023. https://www.arc.gov/distressed-designation-and-county-economic-status-classification-system/

12. Mariotto AB, Feuer EJ, Howlader N, Chen HS, Negoita S, Cronin KA. Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic. *JNCI: Journal of the National Cancer Institute*. 2023;115(9):1109-1111. doi:10.1093/jnci/djad086

13. Zhang X, El-Serag HB, Thrift AP. Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age–Period–Cohort Analysis. *Cancer Epidemiology, Biomarkers & Prevention*. 2020;29(1):88-94. doi:10.1158/1055-9965.EPI-19-1052

14. Rich NE, Yopp AC, Singal AG, Murphy CC. Hepatocellular Carcinoma Incidence is Decreasing Among Younger Adults in the United States. *Clin Gastroenterol Hepatol*. 2020;18(1):242-248.e5. doi:10.1016/j.cgh.2019.04.043

15. Han J, Wang B, Liu W, et al. Declining disease burden of HCC in the United States, 1992–2017: A population-based analysis. *Hepatology*. 2022;76(3):576. doi:10.1002/hep.32355

16. Shiels MS, O'Brien TR. Declining U.S. Hepatocellular Carcinoma Rates, 2014–2017. *Clin Gastroenterol Hepatol*. 2022;20(2):e330-e334. doi:10.1016/j.cgh.2021.02.011

17. Thrift AP, Liu KS, Raza SA, El-Serag HB. Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States. *Clin Gastroenterol Hepatol*. 2023;21(9):2418-2420.e3. doi:10.1016/j.cgh.2022.07.034

18. Shah J, Okubote T, Alkhouri N. Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. *Gastroenterol Hepatol (N Y)*. 2018;14(7):407-414.

19. Yu EL, Schwimmer JB. Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease. *Clin Liver Dis (Hoboken)*. 2021;17(3):196-199. doi:10.1002/cld.1027

20. Cowell E, Patel K, Heczey A, et al. Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. *J Pediatr Gastroenterol Nutr*. 2019;68(5):695-699. doi:10.1097/MPG.0000000000002285

21. Zhang W, Sun B. Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database. *Oncotarget*. 2015;6(2):633-641.

22. Ren J, Tong YM, Cui RX, et al. Comparison of survival between adolescent and young adult vs older patients with hepatocellular carcinoma. *World J Gastrointest Oncol*. 2020;12(12):1394-1406. doi:10.4251/wjgo.v12.i12.1394

23. Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. *Journal of Hepatology*. 2013;58(4):724-729. doi:10.1016/j.jhep.2012.11.009

24. Lee YT, Wang JJ, Luu M, et al. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. *J Natl Cancer Inst*. 2021;113(11):1531-1541. doi:10.1093/jnci/djab079

25. Kehm RD, Spector LG, Poynter JN, Vock DM, Altekruse SF, Osypuk TL. Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival? *Cancer*. 2018;124(20):4090-4097. doi:10.1002/cncr.31560

26. Delavar A, Barnes JM, Wang X, Johnson KJ. Associations Between Race/Ethnicity and US Childhood and Adolescent Cancer Survival by Treatment Amenability. *JAMA Pediatrics*. 2020;174(5):428-436. doi:10.1001/jamapediatrics.2019.6074

27. Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/Ethnic Disparities in Access to Care and Survival for Patients With Early-Stage Hepatocellular Carcinoma. *Archives of Surgery*. 2010;145(12):1158-1163. doi:10.1001/archsurg.2010.272

28. Kahla JA, Siegel DA, Dai S, et al. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. *Pediatr Blood Cancer*. 2022;69(10):e29763. doi:10.1002/pbc.29763

29. Wadhwani SI, Ge J, Gottlieb L, et al. Racial/Ethnic Disparities in Wait List Outcomes Are Only Partly Explained by Socioeconomic Deprivation Among Children Awaiting Liver Transplantation. *Hepatology*. 2022;75(1):115-124. doi:10.1002/hep.32106

30. Ebel NH, Lai JC, Bucuvalas JC, Wadhwani SI. A Review of Racial, Socioeconomic, and Geographic Disparities in Pediatric Liver Transplantation. *Liver Transpl*. 2022;28(9):1520-1528. doi:10.1002/lt.26437

31. Zhou K, Pickering TA, Gainey CS, et al. Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. *JNCI Cancer Spectr*. 2020;5(1):pkaa100. doi:10.1093/jncics/pkaa100

32. Glavas D, Bao QR, Scarpa M, et al. Treatment and Prognosis of Fibrolamellar Hepatocellular Carcinoma: a Systematic Review of the Recent Literature and Meta-analysis. *J Gastrointest Surg*. 2023;27(4):705-715. doi:10.1007/s11605-023-05621-z

33. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. *United European Gastroenterol J*. 2013;1(5):351-357. doi:10.1177/2050640613501507

34. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. *Cancer*. 2006;106(6):1331-1338. doi:10.1002/cncr.21703

35. Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. *Eur J Cancer*. 2013;49(12):2698-2704. doi:10.1016/j.ejca.2013.04.012

36. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary Care Physicians Who Treat Blacks and Whites. *New England Journal of Medicine*. 2004;351(6):575-584. doi:10.1056/NEJMsa040609

Table 1. Incidence of hepatocellular carcinoma cases, with multivariable negative binomial analysis, United States Cancer Statistics database, 2003-2020

Variable	0-19 years				20+ years			
	Count	Rate (95%CI)	RR (95%CI)	p-value	Count	Rate (95%CI)	RR (95%CI)	p-value
Total	813	0.056 (0.052-0.060)	~	~	354,536	7.793 (7.767-7.819)	~	~
Sex								
Male	431	0.058 (0.053-0.064)	ref	ref	273,079	12.891 (12.842-12.941)	ref	ref
Female	382	0.054 (0.048-0.059)	0.93 (0.81-1.07)	0.31	81,457	3.363 (3.339-3.386)	0.30 (0.29-0.32)	<0.0001
Race and Ethnicity								
NHW	444	0.056 (0.051-0.061)	ref	ref	205,091	6.150 (6.123-6.177)	ref	ref
NHB	106	0.048 (0.039-0.058)	0.84 (0.67-1.05)	0.12	52,670	10.819 (10.724-10.914)	1.92 (1.79-2.06)	<0.0001
NHAIAN	~	~	0.69 (0.28-1.67)	0.41	3,917	13.439 (13.002-13.886)	2.21 (2.02-2.40)	<0.0001
NHAPI	52	0.069 (0.051-0.090)	1.12 (0.83-1.51)	0.46	28,918	14.706 (14.533-14.881)	2.38 (2.21-2.57)	<0.0001
Hispanic	185	0.058 (0.050-0.067)	1.02 (0.85-1.22)	0.86	56,815	14.042 (13.922-14.162)	1.83 (1.71-1.96)	<0.0001
Stage								
Localized	299	0.021 (0.018-0.023)	~	~	168,952	3.707 (3.690-3.725)	~	~
Regional	247	0.017 (0.015-0.019)	~	~	88,873	1.948 (1.935-1.961)	~	~
Distant	234	0.016 (0.014-0.018)	~		51,587	1.137 (1.127-1.147)	~	~
Histology								
HCC (non-fHCC)	492	0.034 (0.031-0.037)	~	~	353,648	7.772 (7.746-7.798)	~	~
fHCC	321	0.022 (0.020-0.024)	~	~	888	0.021 (0.020-0.023)	~	~

Rates per 100,000 persons. Three decimal places were used for pediatric ages instead of expressing rates per 1 million. Abbreviations: fibrolamellar hepatocellular carcinoma (fHCC), hepatocarcinoma (HCC), Non-Hispanic white (NHW), Non-Hispanic Black (NHB), Non-Hispanic American Indian/Alaska Native (NHAIAN), Non-Hispanic Asian and Pacific Islanders (NHAPI), relative risk (RR), confidence intervals (CI), reference group (ref), too few cases to calculate (~).

Table 2. Relative survival of cases with hepatocellular carcinoma, National Program of Cancer Registries, 2001-2019

Variable	Count	Total Relative Survival % (95%CI)	Count	2001-2007 Relative Survival (95%CI)	Count	2008-2019 Relative Survival (95%CI)
Total						
0-19	702	46.4 (42.4-50.3)	256	37.6 (31.7-43.5)	446	52.3 (47.0-57.3)
20+	256,704	20.7 (20.5-20.9)	62,722	16.4 (16.1-16.7)	193,982	22.2 (22.0-22.4)
Sex						
Male						
0-19	381	46.8 (41.4-52.0)	145	37.4 (29.5-45.2)	236	53.5 (46.2-60.2)
20+	198,821	19.9 (19.7-20.1)	48,256	15.80 (15.4-16.1)	150,565	21.2 (21.0-21.5)
Female						
0-19	321	46.0 (40.0-51.7)	111	37.9 (28.9-46.8)	210	50.9 (43.1-58.2)
20+	57,883	23.7 (23.3-24.1)	14,466	18.50 (17.8-19.2)	43,417	25.5 (25.0-26.0)
Race and Ethnicity						
NHW						
0-19	372	48.9 (43.3-54.1)	138	41.4 (33.1-49.5)	234	53.6 (46.3-60.4)
20+	142,392	19.8 (19.5-20.0)	34,938	15.7 (15.3-16.1)	107,454	21.2 (20.9-21.5)
NHB						
0-19	93	41.1 (30.4-51.5)	34	29.5 (15.4-45.1)	59	48.9 (34.5-61.8)
20+	39,152	17.3 (16.9-17.8)	9,045	11.5 (10.8-12.2)	30,107	19.2 (18.6-19.7)
NHAIAN						
0-19	~	~	~	~	~	~
20+	2,550	17.0 (15.3-18.9)	483	13.0 (10.0-16.4)	2,067	18.0 (15.9-20.2)
NHAPI						
0-19	44	41.0 (25.7-55.7)	19	15.8 (3.9-35.0)	25	63.2 (39.2-79.9)
20+	21,971	31.4 (30.7-32.1)	6,578	26.0 (24.9-27.1)	15,393	33.9 (33.0-34.8)
Hispanic						
0-19	170	43.1 (34.9-51.0)	57	36.9 (24.6-49.2)	113	47.3 (36.6-57.3)
20+	44,990	20.8 (20.4-21.3)	10,372	16.7 (15.9-17.4)	34,618	22.0 (21.5-22.6)
Stage						
Localized						
0-19	255	75.1 (68.8-80.4)	79	71.1 (59.7-79.8)	176	77.4 (69.5-83.5)
20+	121,569	33.6 (33.3-34.0)	26,475	28.0 (27.5-28.6)	95,094	35.3 (34.9-35.6)
Regional						
0-19	204	44.5 (37.1-51.6)	70	37.3 (26.1-48.4)	134	48.6 (38.9-57.7)
20+	65,784	12.0 (11.7-12.2)	15,549	10.1 (9.6-10.6)	50,235	12.5 (12.2-12.9)
Distant						
0-19	215	14.1 (9.5-19.7)	94	7.5 (3.3-13.9)	121	20.9 (13.3-29.6)
20+	39,568	3.5 (3.2-3.7)	10,502	3.2 (2.9-3.6)	29,066	3.5 (3.3-3.8)
Histology						
HCC (non-fHCC)						
0-19	440	44.8 (39.8-49.7)	167	32.4 (25.5-39.6)	273	53.5 (46.7-59.8)
20+	255990	20.7 (20.5-20.9)	62,478	16.3 (16.0-16.7)	193512	22.1 (21.9-22.4)
fHCC						
0-19	262	49.3 (42.7-55.6)	89	47.3 (36.7-57.2)	173	50.7 (42.1-58.6)

| 20+ | 714 | 35.3 (31.9-39.8) | 244 | 33.3 (27.3-39.5) | 470 | 37.6 (32.4-42.7) |

Abbreviations: fibrolamellar hepatocellular carcinoma (fHCC), hepatocarcinoma (HCC), Non-Hispanic white (NHW), Non-Hispanic Black (NHB), Non-Hispanic American Indian/Alaska Native (NHAIAN), Non-Hispanic Asian and Pacific Islanders (NHAPI), relative risk (RR) confidence intervals (CI), too few cases to calculate (~), 0-19 years of age (0-19), 20 years or older (20+).

Figure 1A. Incidence trend of hepatocellular carcinoma cases in children and adolescents. B. Incidence trend of hepatocellular carcinoma cases in adults. C-E. Rate by stage. D. sex. E. race/ethnicity. Rates are per 100,000 persons. Abbreviations: annual percent change (APC), average annual percent change (AAPC), non-Hispanic white (NHW), Non-Hispanic Black (NHB), Non-Hispanic American Indian/Alaska Native (NHAIAN), Non-Hispanic Asian/Pacific Islander (NHAPI). Non-Hispanic American Indian/Alaska Native were excluded in pediatric ages due to <6 cases. Incidence trends were measured in APC and AAPC and calculated using Joinpoint software and defined as significant if different from zero using an alpha of 0.05. Error bars indicate confidence intervals.

Figure 2 5-year relative survival of patients with hepatocellular carcinoma A. stage. B. sex. C. race/ethnicity. Abbreviations: Non-Hispanic (NH), American Indian/Alaskan Native (NHAIAN), Asian/Pacific Islander (NHAPI), annual percent change (APC). Non-Hispanic American Indian/Alaska Native were excluded in pediatric due to <6 cases. Error bars indicate confidence intervals.

Figure 3 A-B 5-year overall survival of patients with hepatocellular carcinoma. A. Pediatric risk factors. B. Adult risk factors C. Modeling of relative hazard against age in adults. Abbreviations: hazard ratio (HR), reference group (ref.), 95% confidence interval (CI), metropolitan (metro), Non-Hispanic American Indian/Alaska Native (NHAIAN) or Non-Hispanic Asian/Pacific Islander (NHAPI). Error bars indicate confidence intervals. P-value was calculated from multivariate Cox analysis for each group; individual subgroups were considered significant if CI did not cross 1 (p<.05).

Figure S1 5-year overall survival of adult (left) and pediatric (right) patients with hepatocellular carcinoma. A. Diagnosis year. B. Stage. C. Histology. Abbreviation: fibrolamellar hepatocellular carcinoma (fHCC), hepatocarcinoma (HCC).

Figure S2 5-year overall survival of adult (left) and pediatric (right) patients with hepatocellular carcinoma. A. Sex. B. Race and ethnicity. C. Socioeconomic status by county. D. Metropolitan status. Abbreviation: metropolitan (metro), Non-Hispanic (NH).

Table S1. Incidence of hepatocellular carcinoma

Total

Age, years	Count	Rate per 100,000 (95% CI)
0-19	813	0.056 (0.052-0.060)
20+	354536	7.793 (7.767-7.819)
0-14	383	0.036 (0.033-0.04)
15-19	430	0.115 (0.104-0.126)
20-29	1304	0.172 (0.163-0.182)
30-39	3027	0.425 (0.410-0.440)
40-64	181614	8.815 (8.774-8.856)
65 +	168591	22.084 (21.979-22.191)

Stage

Localized

Age, years	Count	Rate per 100,000 (95% CI)
0-19	299	0.021 (0.018-0.023)
20+	168952	3.707 (3.690-3.725)
0-14	149	0.014 (0.012-0.016)
15-19	150	0.040 (0.034-0.047)
20-29	529	0.070 (0.064-0.076)
30-39	1353	0.190 (0.180-0.201)
40-64	86162	4.173 (4.145-4.201)
65 +	80908	10.584 (10.510-10.657)

Regional

Age, years	Count	Rate per 100,000 (95% CI)
0-19	247	0.017 (0.015-0.019)
20+	88873	1.948 (1.935-1.961)
0-14	114	0.011 (0.009-0.013)
15-19	133	0.036 (0.030-0.042)
20-29	351	0.046 (0.042-0.052)
30-39	783	0.110 (0.102-0.118)
40-64	47378	2.300 (2.280-2.321)
65 +	40361	5.277 (5.226-5.330)

Distant

Age, years	Count	Rate per 100,000 (95% CI)
0-19	234	0.016 (0.014-0.018)
20+	51587	1.137 (1.127-1.147)
0-14	102	0.010 (0.008-0.012)
15-19	132	0.035 (0.030-0.042)
20-29	312	0.041 (0.037-0.046)

30-39	615	0.086 (0.079-0.093)
40-64	26743	1.302 (1.286-1.317)
65 +	23917	3.141 (3.101-3.182)

Histology

HCC (non-fHCC)

0-19	492	0.034 (0.031-0.037)
20+	353648	7.772 (7.746-7.798)
0-14	272	0.026 (0.023-0.029)
15-19	220	0.059 (0.051-0.067)
20-29	996	0.132 (0.124-0.140)
30-39	2904	0.408 (0.394-0.423)
40-64	181380	8.803 (8.762-8.844)
65 +	168368	22.055 (21.949-22.161)

Fibrolamellar HCC

0-19	321	0.022 (0.020-0.024)
20+	888	0.021 (0.02-00.023)
0-14	111	0.010 (0.009-0.013)
15-19	210	0.056 (0.049-0.064)
20-29	308	0.041 (0.036-0.046)
30-39	123	0.017 (0.014-0.020)
40-64	234	0.012 (0.011-0.014)
65 +	223	0.029 (0.026-0.034)

Metropolitan status

Metropolitan Counties

0-19	710	0.057 (0.053-0.062)
20+	305514	8.125 (8.096-8.154)
0-14	330	0.040 (0.033-0.041)
15-19	380	0.120 (0.108-0.132)
20-29	1139	0.174 (0.164-0.185)
30-39	2731	0.443 (0.426-0.460)
40-64	157353	9.134 (9.089-9.180)
65+	144291	23.167 (23.047-23.288)

Nonmetropolitan Counties

0-19	102	0.049 (0.040-0.060)
20+	46904	6.203 (6.146-6.260)
0-14	52	0.035 (0.026-0.046)

15-19	50	0.090 (0.068-0.121)
20-29	161	0.166 (0.141-0.193)
30-39	279	0.307 (0.272-0.346)
40-64	23334	7.210 (7.116-7.305)
65+	23130	17.121 (16.90-17.345)
Sex		
Male		
0-19	431	0.058 (0.053-0.064)
20+	273079	12.891 (12.842-12.941)
0-14	219	0.040 (0.035-0.046)
15-19	212	0.111 (0.096-0.127)
20-29	791	0.206 (0.192-0.220)
30-39	2191	0.616 (0.590-0.642)
40-64	149793	14.978 (14.902-15.055)
65+	120304	35.768 (35.563-35.973)
Female		
0-19	382	0.054 (0.048-0.059)
20+	81457	3.363 (3.339-3.386)
0-14	164	0.032 (0.027-0.037)
15-19	218	0.120 (0.104-0.137)
20-29	513	0.138 (0.127-0.151)
30-39	836	0.234 (0.218-0.250)
40-64	31821	3.002 (2.968-3.035)
65+	48287	11.332 (11.230-11.434)
Race and Ethnicity		
NH White		
0-19	444	0.056 (0.051-0.061)
20+	205091	6.150 (6.123-6.177)
0-14	200	0.035 (0.030-0.040)
15-19	244	0.117 (0.103-0.133)
20-29	594	0.141 (0.130-0.152)
30-39	971	0.235 (0.221-0.250)
40-64	99148	6.831 (6.788-6.874)
65+	104378	17.843 (17.735-17.953)
NH Black		
0-19	106	0.048 (0.039-0.058)

20+	52670	10.819 (10.724-10.914)
0-14	47	0.029 (0.022-0.039)
15-19	59	0.103 (0.078-0.132)
20-29	267	0.248 (0.219-0.279)
30-39	775	0.830 (0.772-0.890)
40-64	32768	13.878 (13.727-14.029)
65+	18860	26.418 (26.036-26.805)
NH American Indian/Alaska Native		
0-19	~	~
20+	3917	13.439 (13.002-13.886)
0-14	~	~
15-19	~	~
20-29	8	0.116 (0.050-0.228)
30-39	28	0.497 (0.330-0.719)
40-64	2322	15.383 (14.760-16.026)
65+	1559	38.116 (36.185-40.127)
NH Asian or Pacific Islander		
0-19	52	0.069 (0.051-0.090)
20+	28918	14.706 (14.533-14.881)
0-14	29	0.052 (0.035-0.074)
15-19	23	0.120 (0.076-0.179)
20-29	156	0.314 (0.267-0.368)
30-39	748	1.512 (1.405-1.625)
40-64	13304	13.357 (13.130-13.587)
65+	14710	48.718 (47.923-49.523)
Hispanic		
0-19	185	0.058 (0.050-0.067)
20+	56815	14.042 (13.922-14.162)
0-14	97	0.040 (0.032-0.048)
15-19	88	0.113 (0.091-0.140)
20-29	244	0.159 (0.140-0.180)
30-39	434	0.317 (0.287-0.348)
40-64	30612	13.915 (13.759-14.072)
65+	25525	45.224 (44.662-45.791)
Socioeconomic Status		
Top 25% Economic Status		

Age	Count	Rate (CI)
0-19	295	0.063 (0.056-0.071)
20+	106,570	7.296 (7.252-7.341)
0-14	140	0.041 (0.034-0.048)
15-19	155	0.130 (0.110-0.152)
20-29	422	0.178 (0.161-0.196)
30-39	1,044	0.437 (0.411-0.464)
40-64	52,432	7.666 (7.600-7.733)
65+	52,672	22.025 (21.836-22.215)
Middle 25-75% Economic Status		
0-19	415	0.053 (0.048-0.058)
20+	201,762	8.139 (8.104-8.175)
0-14	188	0.033 (0.028-0.038)
15-19	227	0.111 (0.097-0.127)
20-29	742	0.176 (0.164-0.189)
30-39	1,593	0.414 (0.394-0.435)
40-64	105,433	9.508 (9.45-9.567)
65+	93,994	22.382 (22.238-22.526)
Bottom 25% Economic Status		
0-19	71	0.050 (0.039-0.064)
20+	35,718	8.310 (8.223-8.397)
0-14	40	0.039 (0.028-0.053)
15-19	31	0.085 (0.058-0.121)
20-29	104	0.153 (0.125-0.185)
30-39	283	0.467 (0.414-0.525)
40-64	18,445	9.858 (9.713-10.003)
65+	16,886	22.463 (22.123-22.806)

3
4
Rates per 100,000 persons. Three decimal places were used for pediatric ages instead of expressing rates per 1 million. Abbreviations: fibrolamellar hepatocellular carcinoma (fHCC), hepatocarcinoma (HCC), Non-Hispanic (NH), confidence intervals (CI), reference group (ref), not applicable (~). The left column indicates year of age.

Table S2. Relative risk of hepatocellular carcinoma incidence

	0-19 years model		20+ years model	
Variable	RR (95%CI)	p-value	RR (95%CI)	p-value
Metro 250K-1M vs Metro >1M	0.97 (0.81-1.17)	0.7662	0.95 (0.89-1.01)	0.0917
Metro <250K vs Metro >1M	0.76 (0.56-1.03)	0.074	0.88 (0.82-0.95)	0.0004
Non-Metro vs Metro >1M	0.88 (0.69-1.13)	0.3151	0.83 (0.78-0.89)	<.0001
Bottom 25% vs Top 25%	0.89 (0.66-1.18)	0.4123	1.09 (1.02-1.17)	0.0076
25-75% vs Top 25%	0.88 (0.77-1.03)	0.1098	1.05 (0.99-1.11)	0.1055
15-19 years vs 0-14 years	3.15 (2.73-3.64)	<.0001	~	~
30-39 years vs 20-29 years	~	~	2.42 (2.18-2.69)	<.0001
40-64 years vs 20-29 years	~	~	55.27 (50.36-60.65)	<.0001
years vs 20-29 years	~	~	154.56 (140.79-169.68)	<.0001

Percentages indicate economic status (e.g. Bottom 25%). Abbreviations: Relative Risk (RR), metropolitan (metro).

Table S3. 5-year relative survival of patients with hepatocellular carcinoma

Total

Age, years	Count	5 Year RS % (95% CI)
0-19	702	46.4 (42.4-50.3)
20+	256,704	20.7 (20.5-20.2)
0-14	334	48.5 (42.8-54.0)
15-19	368	43.6 (38.1-49.0)
20-29	1129	44.4 (41.4-47.0)
30-39	2,581	36.1 (34.2-38.3)
40-64	142,595	22.7 (22.5-23.2)
65 +	110,399	17.0 (16.7-17.1)

Total 2001-2007

0-19	256	37.6 (31.7-43.5)
20+	62,722	16.4 (16.1-16.7)
0-14	118	38.2 (29.5-46.9)
15-19	138	37.1 (29.1-45.1)
20-29	372	33.8 (29.0-38.6)
30-39	960	30.8 (27.9-33.7)
40-64	34,578	19.9 (19.0-19.9)
65 +	26,812	11.5 (11.0-11.9)

Total 2008-2020

0-19	446	52.3 (30.1-57.4)
20+	193,982	22.2 (22.0-22.4)
0-14	216	58.4 (50.9-65.1)
15-19	230	46.3 (38.9-53.5)
20-29	757	50.6 (46.6-54.4)
30-39	1,621	39.4 (36.7-42.0)
40-64	108,017	23.8 (23.5-24.1)
65 +	83,587	19.1 (18.7-19.5)

Stage
Localized

0-19	255	75.1 (68.8-80.4)
20+	121,569	33.6 (33.3-14.9)
0-14	128	79.0 (70.1-19.6)
15-19	127	71.4 (61.7-15.0)
20-29	455	71.4 (66.6-16.1)
30-39	1107	57.8 (54.6-14.4)
40-64	67,560	36.9 (36.5-37.3)
65 +	52,447	27.7 (27.2-18.3)

Regional

0-19	204	44.5 (37.1-51.6)
20+	65,784	12.0 (11.7-5.2)
0-14	90	49.6 (38.2-14.5)
15-19	114	40.4 (30.7-5.1)
20-29	298	34.8 (29.0-10.8)
30-39	688	23.0 (19.7-4.9)
40-64	37,815	13.0 (12.6-13.4)

65 +	26,983	9.70 (9.3-13.1)
Distant		
0-19	215	14.1 (9.5-28.2)
20+	39,568	3.5 (3.2-33.6)
0-14	101	14.0 (7.6-22.7)
15-19	114	15.0 (8.9-23.0)
20-29	288	15.0 (11.0-8.2)
30-39	544	11.5 (8.9-31.1)
40-64	22,062	3.3 (3.1-34.0)
65 +	16,674	3.1 (2.8-8.0)
Histology		
HCC (non-fHCC)		
0-19	440	44.8 (39.8-49.7)
20+	255,990	20.7 (20.5-20.9)
0-14	245	49.5 (42.8-55.9)
15-19	195	38.5 (31.1-45.9)
20-29	861	47.0 (43.4-50.5)
30-39	2,475	35.7 (33.7-37.8)
40-64	142,411	22.7 (22.5-23.0)
65 +	110,243	17.0 (16.7-17.3)
Fibrolamellar HCC		
0-19	262	49.3 (42.7-55.6)
20+	714	35.3 (31.9-39.8)
0-14	89	52.5 (40.8-62.9)
15-19	173	47.8 (39.6-55.5)
20-29	268	36.0 (30.2-42.6)
30-39	106	44.8 (34.2-54.8)
40-64	184	37.7 (30.1-45.3)
65 +	156	26.6 (18.3-35.7)
Metropolitan Status		
Metropolitan Counties		
0-19	611	47.3 (43.0-51.5)
20+	223,838	21.3 (21.1-21.5)
0-14	287	51.4 (45.1-57.3)
15-19	324	43.8 (37.9-49.5)
20-29	999	45.3 (41.9-48.6)
30-39	2,348	35.7 (33.6-37.8)
40-64	124,715	23.3 (23.0-23.5)
65+	95,776	17.6 (17.2-17.9)
Nonmetropolitan Counties		
0-19	91	40.7 (30.1-51.0)
20+	32,814	16.9 (16.4-17.4)
0-14	47	43.6 (28.6-57.6)
15-19	44	37.4 (22.8-52.0)
20-29	130	36.5 (27.7-45.4)
30-39	232	40.2 (33.5-46.9)
40-64	17,847	18.8 (18.2-19.5)

65+	14,605	13.5 (12.7-14.3)
Sex		
Male		
0-19	381	46.8 (41.4-52.0)
20+	198,821	19.9 (19.7-20.1)
0-14	197	51.8 (44.2-58.9)
15-19	184	41.6 (34.0-49.0)
20-29	695	39.6 (35.7-43.5)
30-39	1,887	33.1 (30.8-35.3)
40-64	118,494	21.4 (21.1-21.7)
65+	77,745	16.5 (16.2-16.8)
Female		
0-19	321	46.0 (40.0-51.7)
20+	57,883	23.7 (23.3-24.1)
0-14	137	48.1 (38.9-56.6)
15-19	184	44.3 (36.3-51.9)
20-29	434	52.0 (46.7-56.9)
30-39	694	44.5 (40.4-48.4)
40-64	24,101	29.4 (28.7-30.0)
65+	32,654	18.2 (17.7-18.8)
Race and Ethnicity		
NH White		
0-19	372	48.9 (43.3-54.1)
20+	142392	19.8 (19.5-20.0)
0-14	170	53.2 (45.0-60.7)
15-19	202	45.2 (37.8-52.4)
20-29	491	48.2 (43.3-53.0)
30-39	822	42.9 (39.2-46.6)
40-64	75,998	22.5 (22.2-22.9)
65+	65081	15.4 (15.1-15.8)
NH Black		
0-19	93	41.1 (30.4-51.5)
20+	39,152	17.3 (16.9-17.8)
0-14	43	49.6 (33.0-64.3)
15-19	50	34.1 (20.8-48.0)
20-29	241	30.7 (24.8-36.9)
30-39	670	24.2 (20.8-27.7)
40-64	25,815	17.1 (16.6-17.6)
65+	12,426	16.9 (16.0-17.8)
NH Indian or Alaska Native		
0-19	~	~
20+	2,550	17.0 (15.3-18.9)
0-14	~	~
15-19	~	~
20-29	7	18.1 (0.8%-54.3)
30-39	17	40.2 (17.2-62.4)
40-64	1,594	18.7 (16.5-21.1)

65+	932	13.4 (10.5-16.5)
NH Asian or Pacific Islander		
0-19	44	41.0 (25.7-55.7)
20+	21971	31.4 (30.7-32.1)
0-14	25	43.3 (22.8-62.4)
15-19	19	38.0 (16.4-59.6)
20-29	140	36.3 (28.1-44.7)
30-39	637	34.1 (30.3-38.0)
40-64	10,712	34.9 (33.9-35.9)
65+	10,482	27.1 (26.1-28.2)
Hispanic		
0-19	170	43.1 (34.9-51.0)
20+	44,990	20.8 (20.4-21.3)
0-14	88	46.8 (35.3-57.4)
15-19	82	38.4 (26.7-50.0)
20-29	219	56.7 (49.3-63.4)
30-39	377	45.0 (39.6-50.3)
40-64	25,496	23.2 (22.6-23.8)
65+	18,898	16.1 (15.5-16.8)
Socioeconomic Status		
Top 25% Economic Status		
0-19	414	44.6 (39.4-49.6)
20+	168,872	19.7 (19.5-19.9)
0-14	191	51.9 (44.2-59.1)
15-19	223	38.1 (31.2-45.0)
20-29	729	45.3 (41.4-49.2)
30-39	1,594	34.8 (32.2-37.3)
40-64	95,327	21.5 (21.2-21.8)
65+	71,222	16.2 (15.9-16.6)
Middle 25-75% Economic Status		
0-19	102	54.1 (43.5-63.6)
20+	29,723	25.6 (25.0-26.1)
0-14	53	47.2 (32.6-60.5)
15-19	49	61.6 (45.9-73.9)
20-29	119	42.2 (32.5-51.6)
30-39	336	40.8 (35.2-46.4)
40-64	15,382	29.1 (28.3-29.9)
65+	13,886	20.4 (19.6-21.3)
Bottom 25% Economic Status		
0-19	155	46.7 (38.1-54.9)
20+	51,635	20.9 (20.5-21.3)
0-14	76	46.5 (34.2-57.9)
15-19	79	47.0 (34.8-58.2)
20-29	252	43.4 (36.9-49.7)
30-39	567	36.0 (31.9-40.1)
40-64	28,218	23.0 (22.4-23.5)
65+	22,598	17.2 (16.5-17.8)

Abbreviations: Relative Survival (RS) confidence intervals (CI) 0-19 years of age (0-19), 20 years or older (20+), fibrolamellar hepatocarcinoma (fHCC), hepatocarcinoma (HCC), Non-Hispanic (NH). The left column indicates years of age.

Figure 1

Figure 2

Figure 3

A

	HR (95%CI)	pvalue	ref.
Bottom 25% Status	1.26 (0.79-1.99)	0.3472	Top 25%
Middle 25-75% Status	0.93 (0.73-1.19)		
fHCC >1-5 years of follow up	1.06 (0.77-1.48)	<0.0001	HCC
fHCC <1 year of follow up	0.38 (0.26-0.55)		
Non-Metro	1.45 (1.01-2.08)	0.053	>1 million
Metro <250K	0.92 (0.56-1.52)		
Metro 250K – 1 million	1.36 (1.02-1.82)		
Distant	7.18 (5.25-9.82)	<0.0001	Localized
Regional	3.10 (2.22-4.32)		
2008-2018	0.69 (0.55-0.86)	0.001	2001-2017
NHAIAN and NHAPI	1.15 (0.73-1.80)	0.0658	NH White
Hispanic	0.94 (0.71-1.25)		
NH Black	1.48 (1.07-2.05)		
Male	1.10 (0.88-1.37)	0.3867	Female
Age (15-19)	1.17 (0.94-1.47)	0.1672	0-14 years

B

	HR (95%CI)	pvalue	ref.
Bottom 25% Status	1.15 (1.13-1.16)	<0.0001	Top 25%
Middle 25-75% Status	1.08 (1.07-1.09)		
fHCC	0.59 (0.54-0.65)	<0.0001	HCC
Non-Metro	1.15 (1.13-1.17)	<0.0001	>1 million
Metro <250K	1.11 (1.09-1.13)		
Metro 250K – 1 million	1.10 (1.9-1.12)		
Distant	3.79 (3.75-3.84)	<0.0001	Localized
Regional	2.07 (2.05-2.09		
Diagnosis Year	0.97/year (0.97-0.97)	<0.0001	2001-2017
NHAIAN and NHAPI	0.78 (0.77-0.80)	<0.0001	NH White
Hispanic	0.97 (0.96-0.99)		
NH Black	1.11 (1.09-1.12)		
Male	1.10 (1.09-1.12)	<0.0001	Female

C

Figure S1

A

Adult

| 2001-2007 | 68230 | 25704 | 17477 | 13608 | 11367 | 9830 |
| 2008-2019 | 215624 | 95663 | 60468 | 41089 | 29076 | 20756 |

Pediatric

| 2001-2007 | 245 | 180 | 124 | 109 | 98 | 90 |
| 2008-2019 | 426 | 307 | 235 | 187 | 160 | 134 |

B

Adult

Localized	136316	81452	55915	40207	30078	22841
Regional	71503	24054	13463	8933	6484	4805
Distant	42954	5783	2559	1547	1077	803

Pediatric

Localized	246	210	183	154	144	129
Regional	195	128	102	91	77	64
Distant	205	110	57	34	24	18

C

Adult

| HCC Other | 283100 | 120914 | 77616 | 54442 | 40239 | 30407 |
| fHCC | 754 | 453 | 329 | 255 | 204 | 179 |

Pediatric

| HCC Other | 426 | 267 | 204 | 171 | 154 | 138 |
| fHCC | 245 | 200 | 155 | 125 | 104 | 86 |

Figure S2

A

Adult

Survival Probability vs Years of Survival

Logrank p <.0001

Pediatric

Survival Probability vs Years of Survival

Logrank p=0.9184

Female	65588	29682	19494	14090	10617	8098
Male	218266	91685	58461	40607	29826	22488

Female	309	206	160	136	120	103
Male	362	261	199	160	138	121

B

Adult

Logrank p <.0001

Pediatric

Logrank p=0.1584

Hispanic	49450	23031	14023	9730	7107	5339
NHBlack	43341	17235	10886	7396	5292	3811
NHAIAN and NHAPI	26199	13311	9675	7388	5879	4694
NHWhite	163829	68162	42937	29849	21871	16503

Hispanic	171	125	97	74	64	52
NHBlack	89	48	39	34	29	28
NHAIAN and NHAPI	47	29	23	17	16	15
NHWhite	359	262	197	168	146	126

C

Adult

Logrank p <.0001

Pediatric

Logrank p=0.8981

Bottom 25%	30723	11571	7071	4781	3422	2523
25-75%	178617	75395	48013	33426	24654	18535
Top 25%	74409	34357	22831	16464	12445	9508

Bottom 25%	60	38	28	25	23	22
25-75%	390	284	215	173	153	126
Top 25%	220	145	118	98	82	76

D

Adult

Logrank p <.0001

Pediatric

Logrank p=0.5880

1 M+	169650	76400	50391	36120	27128	20795
250K-1M	58558	23745	14689	9925	7155	5232
<250K	20625	8108	4936	3357	2376	1748
Non-Metro	34966	13086	7910	5279	3770	2798

1 M+	407	290	225	183	157	135
250K-1M	140	94	71	58	53	48
<250K	40	26	21	17	15	13
Non-Metro	84	57	42	38	33	28